Helix BioPharma Valuation
| HBP Stock | CAD 1.00 0.05 5.26% |
Today, the firm appears to be overvalued. Helix BioPharma Corp retains a regular Real Value of C$0.82 per share. The prevalent price of the firm is C$1.0. Our model calculates the value of Helix BioPharma Corp from evaluating the firm fundamentals such as Shares Owned By Insiders of 2.15 %, return on asset of -4.59, and Return On Equity of -22.21 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Helix BioPharma's valuation include:
Price Book 77.464 | Enterprise Value 45.5 M | Enterprise Value Ebitda (6.36) |
Overvalued
Today
Please note that Helix BioPharma's price fluctuation is out of control at this time. Calculation of the real value of Helix BioPharma Corp is based on 3 months time horizon. Increasing Helix BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Helix BioPharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Helix Stock. However, Helix BioPharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0 | Real 0.82 | Hype 1.0 | Naive 1.12 |
The intrinsic value of Helix BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Helix BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Helix BioPharma Corp helps investors to forecast how Helix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Helix BioPharma more accurately as focusing exclusively on Helix BioPharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Helix BioPharma's intrinsic value based on its ongoing forecasts of Helix BioPharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Helix BioPharma's closest peers.
Helix BioPharma Cash |
|
Helix Valuation Trend
Knowing Helix BioPharma's actual value is paramount for traders when making sound investment determinations. Using both Helix BioPharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Helix BioPharma Total Value Analysis
Helix BioPharma Corp is currently projected to have takeover price of 45.49 M with market capitalization of 49.02 M, debt of 1.58 M, and cash on hands of 938 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Helix BioPharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
45.49 M | 49.02 M | 1.58 M | 938 K |
Helix BioPharma Asset Utilization
One of the ways to look at asset utilization of Helix is to check how much profit was generated for every dollar of assets it reports. Helix BioPharma retains a negative application of resources of -4.59 (percent), losing C$0.0459 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Helix BioPharma Corp shows how discouraging it operates for each dollar spent on its resources.Helix BioPharma Ownership Allocation
Helix BioPharma Corp has a total of 49.02 Million outstanding shares. Roughly 97.85 (percent) of Helix BioPharma outstanding shares are held by general public with 2.15 % owned by insiders and only 0.0 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Helix BioPharma Profitability Analysis
Net Loss for the year was (9.26 M) with profit before overhead, payroll, taxes, and interest of 0.About Helix BioPharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Helix BioPharma Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Helix BioPharma Corp based exclusively on its fundamental and basic technical indicators. By analyzing Helix BioPharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Helix BioPharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Helix BioPharma. We calculate exposure to Helix BioPharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Helix BioPharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -14 K | -13.3 K | |
| Pretax Profit Margin | (4.70) | (4.94) | |
| Operating Profit Margin | (2.86) | (3.00) | |
| Net Loss | (4.71) | (4.94) | |
| Gross Profit Margin | 0.68 | 0.69 |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.